Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Ensysce Biosciences, Inc. on August 25, 2026. The filing addresses critical regulatory status updates regarding Nasdaq listing compliance and the implications of a recent acquisition.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status and corporate events.
Material Changes and Regulatory Status
- Stockholders' Equity Compliance: Nasdaq determined the Company complies with the $2.5 million stockholders' equity requirement (Rule 5550(b)(1)) as of August 25, 2026. However, the Company remains subject to delisting if it fails to evidence this compliance in its next periodic SEC report.
- Minimum Bid Price: The Company received an additional 180-day extension (until February 22, 2027) to regain compliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)), which was previously non-compliant as of February 25, 2026.
- Acquisition and Change of Control: Following the acquisition of Cy Biopharma, Inc. on August 5, 2026, Nasdaq notified the Company on August 25, 2026, that the transaction constitutes a Change of Control under Rule 5110(a).
Outlook, Risks, and Management Commentary
Management intends to submit a timely initial listing application to satisfy Nasdaq's initial listing criteria required due to the Change of Control. The Company believes it will evidence equity compliance in its next periodic report. A significant risk identified is that failure to meet the new initial listing requirements prior to shareholder approval of the preferred stock conversion will result in a suspension of trading of the Company's securities.
Key Facts for Investor Verification
- Verify the Company's ability to evidence $2.5 million in stockholders' equity in the next periodic SEC filing to avoid immediate delisting.
- Monitor the status of the initial listing application required due to the Cy Biopharma acquisition and Change of Control.
- Track the stock price to ensure it meets the $1.00 minimum bid price requirement by the February 22, 2027 deadline.
- Confirm the timeline for shareholder approval of the preferred stock conversion related to the Cy Transaction.